CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $59.07, moving -3.46% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.1%. Elsewhere, the Dow gained 0.57%, while the tech-heavy Nasdaq lost 0.33%.
The company's shares have seen an increase of 12.98% over the last month, surpassing the Medical sector's gain of 0.86% and the S&P 500's gain of 2.57%.
Analysts and investors alike will be keeping a close eye on the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.31 per share, which would represent a year-over-year decline of 29.7%. Alongside, our most recent consensus estimate is anticipating revenue of $8.47 million, indicating a 1311.83% upward movement from the same quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of -$6.57 per share and a revenue of $36.16 million, signifying shifts of -51.38% and -3.11%, respectively, from the last year.
Investors should also take note of any recent adjustments to analyst estimates for CRISPR Therapeutics AG. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. CRISPR Therapeutics AG presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 97, this industry ranks in the top 40% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CRISPR Therapeutics AG (CRSP): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
